Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company based in Seattle, Washington, renowned for pioneering oncology and hematology therapeutics. The company leverages its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to develop novel immunotherapeutic candidates aimed at enhancing cancer treatment outcomes.
Aptevo's robust pipeline includes APVO436, a clinical candidate targeting acute myeloid leukemia (AML), as well as preclinical candidates ALG.APV-527 and APVO603. These candidates utilize the company's versatile technology platforms to generate bispecific and multi-specific antibody candidates that harness the human immune system to target cancer cells.
Recently, Aptevo announced a reverse stock split aimed at regaining compliance with NASDAQ's minimum bid price requirement. The split is part of a strategic plan approved by the shareholders and aims to reduce the number of outstanding shares, thereby increasing the share price.
Among its promising projects, APVO436 has shown significant clinical benefits in combination with venetoclax and azacitidine for frontline AML treatment. The company is preparing to initiate a Phase 1b/2 dose optimization study, further exploring its efficacy. Additionally, ALG.APV-527 is in a Phase 1 trial for multiple solid tumor types, showing early signs of clinical activity and biological effectiveness.
Aptevo's culture of innovation and collaboration has attracted leading minds from pioneering biotech firms, fostering an environment conducive to groundbreaking research and development. The company's latest news highlights ongoing initiatives, such as presenting new data at major conferences and securing strategic partnerships to advance its clinical programs.
Financially, Aptevo remains focused on clinical development and operational efficiency. In recent quarters, the company has reported decreases in research and development expenses due to the transition between phases of its clinical studies. General and administrative expenses have also seen reductions, primarily attributed to lower employee and consulting costs.
Looking ahead, Aptevo continues to advance its pipeline with the aim of transforming cancer treatment paradigms. This commitment is underscored by their participation in major industry conferences and ongoing collaborations with leading CROs and biopharmaceutical firms.
Aptevo Therapeutics (NASDAQ:APVO) provided a significant update on its APVO436 Phase 1 clinical trial, revealing that patient dosing in cohorts 1-8 has been completed, with 36 patients enrolled. Encouragingly, no dose-limiting toxicities were noted in cohorts 5-8. Notably, two patients in cohort 6 achieved complete remission, highlighting potential efficacy. As the trial advances into cohort 9, Aptevo remains focused on improving patient outcomes. The company’s ADAPTIR platform continues to facilitate innovative bispecific antibody development, targeting cancers effectively.
Aptevo Therapeutics announced the launch of its new ADAPTIR-FLEX platform technology and introduced bispecific therapeutic candidate APVO442, targeting PSMA and CD3 for prostate cancer treatment. APVO442 aims to enhance binding strength to tumor antigens while maintaining a low affinity for T cells, potentially improving therapeutic outcomes. The company reported success in earlier clinical trials of its other candidate, APVO436, with two patients achieving complete remission. These advancements signify Aptevo's commitment to developing innovative immuno-oncology therapies.
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced an unsolicited non-binding offer from Tang Capital Partners, LP to acquire all outstanding shares of Aptevo not already owned for $50.00 per share. The Board of Directors will evaluate this proposal while fulfilling their fiduciary duties. They caution that no decisions have been made and that there are no guarantees of an accepted definitive offer. Shareholders do not need to act at this time. Aptevo is a biotechnology company focused on developing immuno-oncology therapeutics using its ADAPTIR™ technology.
Aptevo Therapeutics and Alligator Bioscience announced a partnership to advance ALG.APV-527, a bispecific antibody targeting solid tumors expressing 5T4. The drug is entering Phase 1 clinical development, with plans to file for Clinical Trial Authorization in early 2021.
Recent data from another candidate, APVO436, showing complete remission in patients enhances confidence in ALG.APV-527's potential. The collaboration aims to explore licensing opportunities as clinical development progresses.
Aptevo Therapeutics reported a net loss of $6.8 million for Q3 2020, slightly improved from $6.9 million in Q3 2019. The company generated $1.5 million in royalties from Pfizer's RUXIENCE, resulting in a 209% increase from the previous quarter. R&D expenses decreased to $4.5 million from $7.6 million in 2019, primarily due to COVID-19 impacts. Aptevo's cash reserves stood at $27.5 million, extending its runway into 2022. The Phase 1/1b trial for APVO436 continues, with promising preliminary results showing complete remission in two patients.
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its participation in the 35th Virtual Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 9-14, 2020. The company will present two posters showcasing advances in its therapies: APVO603, which enhances anti-tumor responses, and ALG.APV-527, which shows a favorable safety profile. Live Q&A sessions for both presentations are scheduled for November 11 and 13. These developments highlight Aptevo's commitment to innovative cancer treatment using its proprietary ADAPTIR bispecific technology.
Aptevo Therapeutics has announced a significant update on its APVO436 Phase 1 trial for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
On November 6, the company reported a second complete remission in Cohort 6, bringing the total to two out of nine patients in this group. Data showed one patient with stable disease, while six experienced disease progression. Enrollment in Cohort 8 has commenced, and preliminary pharmacokinetic modeling indicates potential for clinical activity in upcoming cohorts.
Aptevo's proprietary ADAPTIR platform underpins this promising therapy, positioning it as a cost-effective alternative to traditional CAR-T therapies.
Aptevo Therapeutics (NASDAQ:APVO) has adopted a limited duration stockholder rights plan to protect its interests and those of its shareholders. Effective from November 8, 2020, the plan will distribute one right for each share of common stock, with a record date of November 23, 2020. The rights become exercisable if a person or group acquires 10% or more of the company's stock without Board approval, allowing existing shareholders to purchase additional shares at a favorable valuation. The plan is set to expire on November 8, 2021.
Aptevo Therapeutics announced significant progress in its ongoing APVO436 Phase 1 clinical trial for treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). A patient in cohort 6 achieved complete remission, with bone marrow blasts decreasing from 29% to 0% after two cycles of treatment. As dosing continues in cohort 7, pharmacokinetic modeling suggests dosing in cohorts 5-8 may yield further clinical responses. Aptevo’s ADAPTIR™ technology is highlighted as a more convenient and cost-effective option compared to traditional CAR-T therapies.
Aptevo Therapeutics (NASDAQ:APVO) announced progress in its APVO436 Phase 1/1b clinical trial, with two patients dosed in cohort 7. A total of 30 patients have been treated, showing no dose-limiting toxicities or drug-induced anti-drug antibodies to date. Preliminary evidence suggested clinical responses in some patients, particularly in cohort 4, which is noteworthy despite one patient's disease progression. The trial is entering a critical stage, with dosing now in a therapeutic range, enhancing prospects for clinical activity.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
What is Aptevo Therapeutics Inc.?
What technologies does Aptevo Therapeutics use?
What are the key clinical candidates of Aptevo Therapeutics?
Where is Aptevo Therapeutics headquartered?
What recent financial measures has Aptevo taken?
What is ADAPTIR™ technology?
What recent achievements has APVO436 made?
What is ALG.APV-527?
How is Aptevo's financial health regarding R&D expenses?
What is Aptevo's approach to innovation?
